Search results
Heard on the Street: Wall Street Is Cheering a New Obesity Pill Candidate. Here's Why.
The Wall Street Journal· 6 days agoYou don’t need a home run to get Wall Street excited about a pill for obesity. When the market...
Narrowing down the main cause behind insulin resistance | Robesonian
The Robesonian· 32 minutes agoDEAR DR. ROACH: What is the main cause for insulin resistance? I was diagnosed with Type 2 diabetes...
Structure Therapeutics Stock Soars on Obesity Pill Data
The Wall Street Journal· 6 days agoShares of Structure Therapeutics jumped more than 45% Monday after a new clinical study boosted...
Structure pill leads to competitive weight loss in obesity study
BioPharma Dive via Yahoo Finance· 6 days agoShares in the company soared by more than 50% as study data showed the pill led to similar levels of...
Weight loss medication complete guide: From Wegovy to Mounjaro
The Telegraph via Yahoo News· 4 days agoThe new generation of weight-loss drugs were initially developed to treat diabetes and work by...
What's the Difference Between Ozempic and Metformin, and Which One Is Right for You?
Parade via Yahoo News· 3 days agoSources Ozempic. FDA. Dr. Avantika Waring, MD, with 9amHealth Dr. Spencer Nadolsky, DO, an obesity...
Structure's obesity pill surpasses expectations in mid-stage study
Reuters via AOL· 6 days ago(Reuters) -Structure Therapeutics said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations ...
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial results
Quartz· 6 days agoIt’s the latest development in the race among several pharmaceutical companies to introduce new...
What a Year on Ozempic Taught Johann Hari
The Atlantic· 2 days agoThe new book’s title is a slanted reference to Ozempic (which doesn’t come in pill form), and to the new class of anti-obesity medications that is...
Structure Therapeutics' stock jumps on weight-loss-pill trial results
Morningstar· 6 days agoStructure Therapeutics Inc.'s American depositary receipts (GPCR) gained more than 6% premarket on Monday after the company said its experimental weight-loss pill achieved ...